Print Page | Close Window

Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)


 0.51 (0.80%)

Market Cap$8,985,651,209

03/30/17  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics Highlights Leadership in Antibody-Drug Conjugate Technology Innovation at the American Association for Cancer Research (AACR) Annual Meeting 03/30/17

Read more

FDA Lifts Clinical Hold on Seattle Genetics’ Phase 1 Trials of Vadastuximab Talirine 03/06/17

Read more


Barclays Global Healthcare Conference 201703/15/17 10:45 a.m. ETView eventCowen and Company 37th Annual Health Care Conference03/08/17 10:40 a.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
© 2014 Seattle Genetics, Inc.